A trial assessing relation between serum Interferon-inducible protein 10 (IP10) levels and HBsAg serum levels in patients with compensated HBeAg-neg-ative chronic hepatitis B (CHBe-) patients treated with tenofovir disoproxil fumarate (TDF)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenofovir disoproxil fumarate (Primary)
Indications Hepatitis B
Focus Pharmacokinetics

Most Recent Events

15 Dec 2015 New trial record
05 Nov 2013 Interim results (n=137) presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight